Studies heart imaging in people with leaky mitral valve and heart failure
Uses cardiac MRI scans to study heart scarring in adults treated with MitraClip.
Plain-language title generated from the registry record
Registry title: Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
Key facts
- Where
- Charlotte, Cincinnati, Cleveland, Falls Church, and Minneapolis, United StatesSee the 5 sites
Where in United States
- Sanger Heart and Vascular InstituteCharlotte, United StatesEnrolling by invitation
- The Christ Hospital Health NetworkCincinnati, United StatesEnrolling by invitation
- Cleveland ClinicCleveland, United StatesEnrolling by invitation
- Inova Fairfax Medical CampusFalls Church, United StatesEnrolling by invitation
- Minneapolis Heart Institute FoundationMinneapolis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Minneapolis Heart Institute Foundation
- Trial code
- NCT07131631
- Record updated
- 23 December 2025
- Original description
This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up. Enrollment will occur at up to eight centers.Read full original descriptionShow less
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up. Enrollment will occur at up to eight centers.
Inclusion: Adult patients (≥ 18 years old) with heart failure and reduced ejection fraction (LVEF < 50% defined by echocardiography), medically and device-optimized according to guidelines, with significant FMR undergoing TEER with FDA-approved MitraClip device (Abbott Structural, USA).
Exclusion: Concomitant PCI and TEER; Prior mitral valve repair or replacement; Congenital heart disease; Stage D heart failure; Uncontrolled atrial fibrillation; Pregnancy; > moderate tricuspid regurgitation; >moderate aortic regurgitation or stenosis; Contraindications or unable to undergo CMR.